Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Allogeneic islets of Langerhans transplantRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(50%)

Phase Distribution

Phase 1/2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1/2Combined phases
2(100.0%)

Highest Phase Reached

Phase 1/2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 1/2

Trials by Phase

Phase 1/22 (100.0%)

Trials by Status

terminated150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
terminatedphase_1_2

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

NCT00672204
completedphase_1_2

Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes

NCT00285233

Clinical Trials (2)

Showing 2 of 2 trials
NCT00672204Phase 1/2

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

Terminated
NCT00285233Phase 1/2

Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes

Completed

All 2 trials loaded

Drug Details

Intervention Type
Biological
Total Trials
2